To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

March 07, 2018

Today's Rundown

Featured Story

Roivant licenses Ligand diabetes drug, founds Metavant, as push into cardiometabolic diseases gathers pace

Roivant Sciences has picked up the rights to Ligand Pharmaceuticals’ glucagon receptor antagonist LGD-6972. The midphase Type 2 diabetes candidate slots into the pipeline of Roivant’s newly minted cardiometabolic disease startup Metavant.

Top Stories

Aptose signs $125M-plus BET inhibitor deal with Ohm Oncology

The partnership for Aptose's third drug candidate comes as the biotech looks set to have its two lead drugs in clinical testing in the coming months.

Eisai, partner Purdue hit phase 3 goals in sleep drug trial

Japanese pharma Eisai and biopharma Purdue have posted positive late-stage results from their partnered sleep drug lemborexant.

Esperion’s LDL treatment hits the mark in phase 3

A 12-week course of Esperion's bempedoic acid lowered patients' LDL cholesterol by 23%, compared to a 5% increase observed in patients who received placebo.

Cancer vaccine startup Oxford Vacmedix taps Asian syndicate for series A cash

A syndicate of South Korean and Chinese investors has powered Oxford Vacmedix (OVM) to a series A round. OVM will use the $12.5 million (£9 million) investment to take vaccines against cervical cancer and other solid tumors into the clinic.

Moderna’s vaccines head steps down as multiple programs undergo phase 1: report

Giuseppe Ciaramella, the leader of Moderna Therapeutics’ infectious diseases business, has jumped to a stealth-mode biotech startup, leaving a long list of clinical programs behind, according to STAT.

Novartis becomes deeper Science 37 partner, as pair aim for 10-trial launch

Big Pharma Novartis is teaming up with virtual clinical trial company Science 37 to boost the Swiss major’s ability to run “site-less” studies.

Special Report—FierceBiotech’s rotten tomatoes and ripening fruit 2017

We started the Rotten Tomatoes special feature last year to spotlight companies that haven't followed through on the tough ethical and scientific demands of the biotech industry. This year, we’re at it again with a bit of a twist: We included companies bruised in 2016 but revived in 2017.

Resources

[Webinar] Driving Market Access through Patient Advocacy: Trends & Opportunities

There’s no magic bullet to successful access but insights from patient advocates and industry experts can help shape future strategies. Learn how in this webinar. Sign up now!

[Whitepaper] Medical Device Innovation: Are You Outrunning The Competition?

The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market?

[Whitepaper] How Life Sciences Companies Use Box for Regulated Content in the Cloud

Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process.

[Whitepaper] CFO's, Is This Part Of Your Corporate TO DO List?

Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals.

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.

[Webinar] Validating a 7 Day Membrane Filtration Sterility Test using Celsis®

Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols.

[Infographic] Evolution of Flexible Commercial Biologics Manufacturing

Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility.

[eBook] Developing Site-specifically Modified ADCs: Using a Chemoenzymatic Approach

Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology.

[Article] Optimizing titer and use of a specific enzyme for generating a fully processed antibody

Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

Events

.